tetomilast
Small moleculeexperimental
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
7
Phase 3
4
Phase 4
0
Earliest trial started May 1, 2003 (NCT00064454)
Timeline
Indications
Mechanism of action
- Phosphodiesterase 4AINHIBITOR
PDE4A inhibitor
- Phosphodiesterase 4INHIBITOR
Phosphodiesterase 4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOc1ccc(-c2nc(-c3cccc(C(=O)O)n3)cs2)cc1OCC- Mol. weight
- 370.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL332750 ↗
Also known as
- 6-(2-(3,4-diethoxyphenyl)thiazol-4-yl)-pyridine-2-carboxylic acid
- opc6535
- opc 6535
- opc-6535
- opc-6535
- opc-6535
- tetomilast
- tetomilast
- tetomilast
- tetomilast
- tetomilast
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00989573 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2009 | Otsuka |
| NCT00874497 | Phase 2 | Mar 1, 2009 | Otsuka |
| NCT00917150 | Phase 2 | Mar 1, 2009 | Otsuka |
| NCT00317369 | Phase 2 | May 1, 2006 | Otsuka |
| NCT00317356 | Phase 2 | May 1, 2006 | Otsuka |
| NCT00092508 | Phase 3 | May 1, 2004 | Otsuka |
| NCT00064441 | Phase 3 | May 1, 2003 | Otsuka |
| NCT00064454 | Phase 3 | May 1, 2003 | Otsuka |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Otsuka | For profit | 8 | 8 | 2 | 2003 |
1 organizations
Page 1 / 1